Q3FY26- Strong numbers barring the US- Revenues grew ~13% YoY to 15520 crore driven mainly by strong growth in India, global specialty portfolio, RoW and Emerging Markets. India growth was strong at 16% to 4999 crore. The US grew 6% YoY with a revenue of 4251 crore (CC term 0.6% growth) due to weakness in generics which was made good by Specialty traction to some extent and currency movements. RoW markets reported growth of ~21% to 2639 crore, mainly due to growth in both generics and specialty. Emerging markets grew ~28% to 3000 crore,...